SciCombinator

Discover the most talked about and latest scientific content & concepts.

YJ Wang, QG Ren, WG Gong, D Wu, X Tang, XL Li, FF Wu, F Bai, L Xu and ZJ Zhang
Abstract
Tau hyperphosphorylation is an important pathological feature of Alzheimer’s disease (AD). To investigate whether escitalopram could inhibit amyloid-β (Aβ)-induced tau hyperphosphorylation and the underlying mechanisms, we treated the rat primary hippocampal neurons with Aβ1-42 and examined the effect of escitalopram on tau hyperphosphorylation. Results showed that escitalopram decreased Aβ1-42-induced tau hyperphosphorylation. In addition, escitalopram activated the Akt/GSK-3β pathway, and the PI3K inhibitor LY294002 blocked the attenuation of tau hyperphosphorylation induced by escitalopram. Moreover, the 5-HT1A receptor agonist 8-OH-DPAT also activated the Akt/GSK-3β pathway and decreased Aβ1-42-induced tau hyperphosphorylation. Furthermore, the 5-HT1A receptor antagonist WAY-100635 blocked the activation of Akt/GSK-3β pathway and the attenuation of tau hyperphosphorylation induced by escitalopram. Finally, escitalopram improved Aβ1-42 induced impairment of neurite outgrowth and spine density, and reversed Aβ1-42 induced reduction of synaptic proteins. Our results demonstrated that escitalopram attenuated Aβ1-42-induced tau hyperphosphorylation in primary hippocampal neurons through the 5-HT1A receptor mediated Akt/GSK-3β pathway.
Tweets*
0
Facebook likes*
0
Reddit*
0
News coverage*
1
Blogs*
0
SC clicks
0
Concepts
Serotonin, Alzheimer's disease, Buspirone, Receptor theory, Buprenorphine, Agonist, Inverse agonist, Receptor antagonist
MeSH headings
-
comments powered by Disqus

* Data courtesy of Altmetric.com